Sipai Health Technology Co (0314) Fair Value & Analysis
Healthcare · HK · Market cap HK$977M
Fair value as of: Aug 13, 2026
From 6 valuation models · updated 2 days ago
Share price +1.4% over the past month.
A solid business, but screening 72% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.3900). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
44‑month range HK$1.18 – HK$42.10 · the HK$1.41 price screens above the HK$0.3900 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Sipai Health Technology Co (0314) currently trades at HK$1.41, while our model-based Fair Value estimate is HK$0.3900, implying the stock looks roughly 72.3% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Sipai Health Technology Co generated revenue of HK$2.1B at a net margin of -6.0%. Revenue declined 61.5% year over year. It earns a return on equity of -12.1%. The balance sheet holds a net cash position of HK$284M. Fundamentals as of Aug 13, 2026
The share trades about 80% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at -72%, 0314 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Asset-Based (HK$0.8600) versus DCF Models (HK$0.4200). Highest evidence: Growth DCF (80).
Notify me when 0314 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business.
Full company description
Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty Pharmacy Business segment provides specialty pharmacies and value-added professional pharmacist services; focuses on innovative medicines for the treatment of oncology; pharmaceutical supply chain network for health insurance services; and other critical illnesses. The Physician Research Assistance Business segment offers pharmaceutical companies and other clinical trial institutions site management organization services, including site feasibility, site initiation, patient recruitment, patient management, data entry and document management, on-site drug management and bio-sample management, site closure, and others; and services for image management in clinical trials. The Health Insurance Services Business segment provides insurance brokerage services to insurance companies; and health management services to insurance carriers and enterprise clients. The company was founded in 2014 and is headquartered in Putuo, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sipai Health Technology Co reported revenue of HK$2.0B in FY2025 versus HK$3.5B in FY2021, a compound −12.7%/yr. Reported net income was −HK$121M in FY2025.
0314 screens 72% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Cardinal Health, Inc CAH | $234.16 | $141.77 | -39% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
Compare Sipai Health Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sipai Health Technology Co (0314) overvalued or undervalued?
What is the fair value of 0314?
What is the quality score of 0314?
What is the revenue of Sipai Health Technology Co (0314)?
What is the net profit margin of 0314?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sipai Health Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.